Gainers
-
vTv Therapeutics Inc. (NASDAQ: VTVT)
shares rose 44 percent to $2.88 in pre-market trading after surging 158.77 percent on Tuesday.
-
Endologix, Inc. (NASDAQ: ELGX) shares
rose 36.6 percent to $2.35 in pre-market trading after the company reported third-quarter preliminary sales of $34.3 million to
$34.7 million. The company narrowed FY18 sales guidance from $145 millionto $155 million, to $150 million to $155 million.
-
Neovasc Inc. (NASDAQ: NVCN) rose 32
percent to $2.97 in pre-market trading after reporting positive 12-week follow-up data from the first U.S. patient implanted
with a Neovasc Reducer. The patient reported improvement in walking abilities and decreased pain.
-
Trevena, Inc. (NASDAQ: TRVN) rose 19.9
percent to $3.19 in pre-market trading after gaining 13.19 percent on Tuesday.
-
J C Penney Company Inc (NYSE: JCP) rose
10.9 percent to $1.73 in pre-market trading after the company named Jill Soltau its new CEO.
-
ADMA Biologics Inc (NASDAQ: ADMA) rose
10.3 percent to $6.51 in pre-market trading after the company disclosed that its subsidiary, ADMA BioCenters, received FDA
approval for third plasma collection center.
-
Tempur Sealy International, Inc. (NYSE: TPX) rose 8.8 percent to $52.62 in pre-market trading after Reuters reported
Mattress Firm is planning to file for bankruptcy as soon as this week.
-
Thomson Reuters Corporation (NYSE: TRI)
rose 6.8 percent to $47.79 in pre-market trading on heavy volume. The company earlier offered preliminary results of buyback.
The company will 'take up and purchase for cancellation ~138.7 million shares at a purchase price of $47 per share'.
-
Alcoa Corporation (NYSE: AA) rose 6.2
percent to $44.15 in pre-market trading. Alcoa is expected to release Q3 results on October 17.
-
Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR) shares rose 6 percent to $13.93 in pre-market trading after gaining 8.94
percent on Tuesday.
-
Banco Bradesco S.A. (NYSE: BBD) rose 5.7
percent to $8.00 in pre-market trading after climbing 7.60 percent on Tuesday.
-
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) rose 5.6 percent to $9.76 in pre-market trading after falling 5.04
percent on Tuesday.
-
Surgery Partners, Inc. (NASDAQ: SGRY)
shares rose 5.4 percent to $16.58 in pre-market trading.
-
NIO Inc. (NYSE: NIO) rose 5.1 percent to
$6.23 in pre-market trading after falling 10.15 percent on Tuesday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and
losers
Losers
-
Oragenics, Inc. (NYSE: OGEN) shares fell
29.7 percent to $2.51 in pre-market after climbing 123.12 percent on Tuesday.
-
DAVIDsTEA Inc. (NASDAQ: DTEA) shares
fell 21.9 percent to $3.25 in pre-market trading after surging 63.14 percent on Tuesday.
-
India Globalization Capital, Inc. (NYSE: IGC) fell 15.2 percent to $11.20 in pre-market trading after rising 46.34 percent
on Tuesday.
-
Level Brands, Inc. (NYSE: LEVB) fell
12.7 percent to $5.25 in pre-market trading.
-
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) fell 11.5 percent to $8.21 in pre-market trading. Kala Pharma said it
commenced an underwritten public offering of 7.50 million shares. Separately, the company said it closed its $110 million
credit facility with funds managed by Athyrium Capital Management.
-
Century Aluminum Company (NASDAQ: CENX) shares fell 10 percent to $10.71 in pre-market trading.
-
Epizyme, Inc. (NASDAQ: EPZM) shares
fell 7.3 percent to $9.00 in pre-market trading after reporting a common stock offering.
-
New Age Beverages Corporation (NASDAQ: NBEV) fell 6.2 percent to $6.85 in pre-market trading after dropping 18.44
percent on Tuesday.
-
Kandi Technologies Group, Inc. (NASDAQ: KNDI) fell 5.2 percent to $5.26 in pre-market trading after gaining 9.06
percent on Tuesday.
-
Grifols, S.A. (NASDAQ: GRFS) shares
fell 5.8 percent to $19.88 in pre-market trading.
-
RPM International Inc. (NYSE: RPM) shares
fell 3.1 percent to $62.00 in pre-market trading. RPM International reported downbeat earnings for its first quarter, while
sales exceeded estimates.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.